Introduction
Multiple myeloma (MM) is an incurable malignancy of terminally differentiated B lineage cells. Myeloma cells are responsive to a variety of growth factors, the most well studied of which are IL-6 (Klein et al., 1995) and insulin-like growth factor I (IGF-I) (Freund et al., 1993; Georgii-Hemming et al., 1996; Ferlin et al., 2000; Ge and Rudikoff, 2000) . While the response of these cells to growth factors has been characterized in considerable detail, no clear picture has emerged concerning the biochemical lesions associated with initiation or progression of this disease. One possible source of such defects may be complex chromosomal aberrations frequently observed in tumor cell karyotypes. A number of studies have recently described nonrandom chromosomal translocations involving the immunoglobulin heavy chain locus as one partner and several other loci represented at varying frequencies (Bergsagel et al., 1996; Iida et al., 1997; Richelda et al., 1997; Chesi et al., 2000; Ho et al., 2001; Kuehl and Bergsagel, 2002) . However, genes proximal to the translocation sites that subsequently become deregulated (i.e. cyclin Dl, fibroblast growth factor receptor 3, and Maf) are, generally, not transforming. Thus, it is presently unclear what role these translocations may play in the initiation or development of the disease. A variety of other potential lesions have also been noted in MM lines or patient samples. For example, abnormalities have been described at the c-myc and L-myc loci in 95% of MM lines tested and approximately 50% of advanced primary MM tumors (Shou et al., 2000) . Again, the biological consequences of such lesions remain to be determined. Mutations have also been observed in a number of other genes frequently associated with transformation. The most prominent of these are N-and K-Ras wherein activating mutations are found in about 39-55% of newly diagnosed patients (Liu et al., 1996; Bezieau et al., 2001) . The frequency of Ras mutations increases with disease progression (Liu et al., 1996; Rowley et al., 2000; Kuehl and Bergsagel, 2002) .
Given the number and variety of potential lesions observed in MM, it would be of benefit to the understanding of this disease if abnormalities directly associated with transformation and/or growth factor independence could be readily detected. As an approach to identification of such biochemical lesions, we have employed expression cloning to identify genes involved in the molecular pathogenesis of myeloma. Herein, we describe isolation of a novel Ras mutant that is transforming and relieves cellular growth factor dependence.
Results

Identification of transforming genes from OPM-2 human MM cell line
To identify genes that may potentially be involved in myeloma development, an expression cDNA library was generated from the OPM-2 cell line. The library was amplified and DNA transfected into low-passage NIH3T3 cells. Transfected cultures were then scored for the development of transformed foci. In total, 23 foci were identified in the initial screen. Genomic DNA was purified from expanded foci and plasmid cDNA clones were rescued (Miki et al., 1989) . The rescued plasmids were reintroduced into NIH3T3 cells to confirm transforming activity. The most highly transforming DNA was designated 23-1 and characterized in detail. Restriction enzyme analysis showed that 23-1 carries a cDNA insert of 981 bp. Nucleotide sequencing revealed an open reading frame of 567 bp flanked by 99 and 315 bp of 5 0 and 3 0 untranslated segments, respectively. The open reading frame predicted a protein of 189 amino acids (21 kDa). A search of GeneBank indicated a 99.5% sequence identity with human c-Ha-Ras with a single mutation involving an A to G conversion at the first nucleotide of codon 117, resulting in the replacement of lysine (AAG) by glutamic acid (GAG) in the 23-1 sequence [H-Ras (K117E)]. We compared transforming activities of H-Ras (K117E) and oncogenic H-Ras (G12V) by NIH3T3 focus formation assay and inoculation of SCID mice. As shown in Table 1 , H-Ras (K117E) effectively induced foci, albeit at a somewhat lower number than H-Ras (G12V). Cells expressing H-Ras (K117E) exhibited a highly transformed phenotype in vivo, inducing tumor growth in SCID mice with the same efficiency as those expressing activated H-Ras (G12V).
Detection of H-Ras mutation in OPM-2 cells
To confirm that the codon 117 mutation was present in the OPM-2 cell line and not a cloning artefact, we generated PCR codon-specific primers flanking the mutation site (Figure 1a ) for the analysis of total cellular RNA. As a control for specificity, the plasmid construct carrying H-Ras (G12V) cDNA with a wildtype sequence in the region of amplification (nucleotides 121-349) was used. As shown in Figure 1b , both wildtype and mutant primer pairs generated DNA fragments of the expected 249 bp size in OPM-2, whereas, in the HRas control sample, a DNA fragment was derived only with the wild-type primer pair This result indicates that the codon 117 mutation exists in the established human OPM-2 MM cell line on one allele, and that the other expresses wild-type H-Ras. To identify the mutated sequence in genomic DNA conclusively, exon 3 of H-ras was amplified by PCR, then subcloned into TOPO cloning vector. After transformation, 50 bacterial clones were subjected to PCR analysis for verification of inserts. In total, 48 PCR mixtures containing inserts from individual clones were screened by nonradioactive SSCP analysis (Hongyo et al., 1993) using an H-ras wild-type genomic construct and genomic DNA from ANBL-6-H-Ras (K117E) as negative and positive controls, respectively (not shown). Two clones (4%) showed the same migration pattern on SSCP gels as the positive control. Plasmid DNA was purified and sequence analysis revealed the presence of the codon 117 mutation in both.
The existence of a second MM line (OPM-1) established from the same patient (Katagiri et al., 1985) provided an opportunity to assess whether the two lines were clonally related and carried the same mutation. Exon 3 of the H-ras gene was PCR amplified from OPM-1, OPM2, H929, and an H-ras wild-type genomic construct and subjected to SSCP analysis. As shown in Figure 1c , OPM-1 and OPM-2 share the same unique banding pattern suggesting that they are, in fact, clonally related and express the 117 mutation.
H-Ras activation in OPM-2 and OPM-1 cell lines
To investigate Ras activation status, we first performed Western blot analysis in the OPM-2 cell line using antibodies specific for each Ras isoform (Figure 2a ). H-, N-, and K-Ras proteins are all expressed in OPM-2. To determine the Ras activation profile, OPM-2 and OPM-1 cell extracts were analysed for Ras and MAP kinase activities. As shown in Figure 2b , c, H-Ras and MAP kinase are constitutively activated, and IL-6 stimulation can up regulate the Ras pathway. However, activation of N-and K-Ras is undetectable in OPM-2. This result is consistent with a previous report indicating that OPM-2 does not harbor activating N-or K-Ras mutations at codons 12, 13, or 61 (Chesi et al., 2001) .
Factor-independent growth of 32D and B9 cells expressing mutant Ras 32D C13 is a nontumorigenic, immature myeloid, murine hematopoietic cell line that is strictly dependent on exogenously supplied interleukin-3 (IL-3) for growth (Takahashi et al., 1994) . B9 is a murine B-cell hybridoma line that requires IL-6 for survival and proliferation (Diamant et al., 1994) . The loss of growth factor dependence is a property that is associated with transformation and tumorigenicity linked to a variety of oncogenes. To investigate whether the H-Ras mutant is capable of inducing growth factor independence, we (Figure 3a) , and B9/H-Ras (K117E) (Figure 3b ) transfectants expressing comparable levels of mutant proteins were compared with their parental cells in the absence of growth factors. 32D cells expressing H-Ras (K117E) mutant were able to grow without IL-3 indefinitely and could be generated repeatedly. Interestingly, expression of H-Ras with a transforming mutation at position 12 in 32D cells did not abrogate the IL-3 dependence in agreement with previous studies (Cristofanelli et al., 2000) . B9 cells expressing H-Ras (K117E) generated by retroviral vector transfection were, similarly, able to grow in the absence of IL-6. To rule out the possibility that the loss of growth factor dependence was because of induction of autocrine growth factor production, supernatants from both 32D and B9 Ras mutant transfectants were tested on parental lines. These supernatants failed to support growth of the respective parental cells. Therefore, H-Ras (K117E) alone can abrogate the growth factor dependence of 32D cells for IL-3 and B9 for IL-6 by a mechanism independent of autocrine growth factor regulation.
To assess the biochemical activity associated with the mutant (K117E) in the 32D and B9 transfectants, cell lysates were analysed for Ras activation and MAP kinase activity. As shown in Figure 4a , neither parental 32D nor vector-transfected lines exhibited activated HRas even when grown in serum or IL-3. In contrast, mutant Ras (K117E) is constitutively activated and the level of activity is not increased by serum or IL-3. A low basal MAPK activity is detected in parental and vector controls, and this activity can be markedly enhanced by IL-3. Higher basal activity is observed in the (K117E) transfectant that can be enhanced by either serum or IL-3. Similar patterns were also noted in 32D cells carrying H-Ras (G12V) (data not shown). In B9 cells, H-Ras (K117E) is also constitutively activated and MAPK activity in serum alone is equivalent to that observed in the controls in the presence of IL-6 (Figure 4b ). This activity can be further elevated by IL-6 treatment.
Enhanced proliferation ofANBL-6/Ras ANBL-6 is an IL-6 dependent human myeloma cell line that does not carry any activating Ras mutations (Bos et al., 1987) . Activating N-and K-Ras mutations have previously been shown to effect growth properties of myeloma cells differentially (Billadeau et al., 1997) . Transfection of the multiple myeloma line ANBL-6 by 0 primer (F) was used with two 3 0 primers specific for either wild type (wt) or mutant (mt). (b) Agarose gel analysis of the PCR fragments: the H-Ras control is a plasmid construct carrying activated H-Ras with a point mutation at position 12. The region between nucleotides 121 and 349 is a wild-type sequence. (c) PCR-SSCP analysis of H-ras wild-type genomic construct and genomic DNA from OPM-1, OPM2, and H929 using a primer pair flanking exon 3 of H-Ras. SSCP analysis of the PCR fragments was performed using silver staining as described in Materials and methods Unusual Ras mutation causing transformation C Crowder et al N-Ras (Q61R) or N-Ras (G12V) resulted in a significant inhibition of apoptosis in the absence of IL-6, as well as an enhanced proliferative response to suboptimal concentrations of IL-6 (Billadeau et al., 1995) . Similar augmentation of cell growth (DNA synthesis) was subsequently observed in the absence or at suboptimal concentrations of IL-6 with both N-Ras mutants and KRas (G12V) (Billadeau et al., 1997) . However, growth of the K-Ras mutant was significantly inhibited in the absence of IL-6, which was attributed to the observation that the N-Ras mutants could inhibit apoptosis whereas the K-Ras mutant could not. We, therefore, analysed the effect of the H-Ras (K117E) mutant and N-Ras (G12V) on the growth of ANBL-6. A population of stable transfectants was obtained following infection with the retroviral vector pFB/neo/H-Ras (K117E) and selection in G418. The optimal IL-6 concentration for the parental ANBL-6 line was found to be 10 ng/ml (Figure 5a ). However, even at this concentration ANBL-6/H-Ras (K117E) cells showed growth augmentation compared to the parental and vector control groups. This effect became more pronounced at lower IL-6 concentrations (Figure 5b, c) . Neither control nor H-Ras-transfected cells grew in the absence of IL-6 (Figure 5d ). Comparison with N-Ras G12V revealed similar growth enhancement most readily observed at lower IL-6 concentrations (Figure 5e-g ). However, this mutant was further able to promote growth in the absence of IL-6 (Figure 5h ) in contrast to K117E. Constitutive activity of H-Ras in transfected cells was confirmed by in vitro analysis (Figure 6a ), wherein Ras activity could not be increased by the addition of exogenous IL-6. In control cells, significant H-Ras activation was observed only in the presence of IL-6 at a concentration of 50 ng/ml. IL-6 independence in some plasma cell tumors and hybridomas has been associated with constitutive activation of singal transducer and activator of transcription 3 (Stat3) (Hilbert et al., 1996; Rawat et al., 2000) . To examine the possibility that Stat signaling might be involved in the altered response to IL-6, we analysed the phosphorylation state of Stat3 in H-Ras-transfected and control ANBL-6 cells. In ANBL-6/H-Ras (K117E), Stat3 tyrosine phosphorylation is undetectable in the absence of IL-6 indicating that the altered response to IL-6 is independent of this pathway (Figure 6b ). Identical results were obtained with the IL-6-independent B9 transfectants (data not shown).
Ras protein expression and activation profile in myeloma cell lines
Activating mutations of K-and N-Ras have been reported in approximately 39-50% of MM tumors and myeloma cell lines (Bezieau et al., 2001; Liu et al., 2001) . We analysed six human myeloma cell lines for Ras protein expression and activation. As shown in Table 2 , H-, N-, and K-Ras proteins are expressed in all lines except SKMM-1, where H-Ras protein is undetectable. In OPM-2, consistent with the above data, HRas is constitutively activated. Three of the six lines express activated N-Ras. The N-Ras-activating mutations in H929 and KMM1 have previously been reported (Chesi et al., 2001) .
Discussion
Common biochemical lesions associated with the initiation and/or progression of MM have been difficult to identify unambiguously. Nonrandom chromosomal translocations have identified several target genes such as fibroblast growth factor receptor 3, cyclin Dl, and Maf that are overexpressed in a significant percentage of myeloma lines (Bergsagel et al., 1996; Chesi et al., 2000; Drach et al., 2000; Kastrinakis et al., 2000) . However, these genes are generally nontransforming and translocations observed in primary tumors appear not to correlate with prognostic indicators or survival (Ho Mutations have also been observed in cellular oncogenes, the most common of which occur in the Ras family (Paquette et al., 1990; Corradini et al., 1994; Liu et al., 1996) . The human Ras family consists of three members (H-, N-, and K-Ras), which have been identified in mutated forms with transforming potential in a variety of human neoplasms (Sebti and Hamilton, 2000) . Most commonly reported activating mutations occur at codons 12, 13, and 61. Ras point mutations can be detected in about 39-55% of newly diagnosed myeloma patients, with N-Ras 61 and K-Ras 12/13 being the most common sites of activating mutations (Neri et al., 1989; Liu et al., 1996; Bezieau et al., 2001; Kalakonda et al., 2001) . It should be noted that considerable controversy exists as to which isoform and which positions are most frequently mutated. Additionally, the expression of a particular mutation in myeloma cells from a single patient appears to vary from a few to nearly 100%. As a result, the role of Ras Figure 3 Expression of mutant Ras leads to factor-independent growth of 32D and B9 cells. Parental, vector transfected, and H-Ras mutant-transfected cells were seeded in triplicate in a medium without growth factors. (a) 2 Â 10 4 32D cells/ml were seeded in RPMI1640/15% heat-inactivated FBS. Cell viability was determined at days 1 and 2. (b) 2Â 10 5 B9 cells/ml were cultured in RPMI1640/10% heat-inactivated serum. Cell viability was determined at days 2 and 4
Unusual Ras mutation causing transformation C Crowder et al mutations in myeloma development also remains unclear. Ras mutations appear to be rare in early-stage disease or in the putative premyeloma condition of monoclonal gammopathy of undetermined significance (MGUS) (Neri et al., 1989; Matozaki et al., 1991; Drach et al., 2000; Bezieau et al., 2001; Kuehl and Bergsagel, 2002) . Pertinent to the present study is the observation made using H-Ras-specific antibody and flow cytometric analysis that H-Ras expression was elevated in 9/23 MM patients with poor prognosis (Liotta, 1988; Tsuchiya et al., 1988) . However, activating mutations in H-Ras, such as those reported for N-and K-Ras, appear to be far less frequent.
In an attempt to use a functional approach to search for transforming genes that may be involved in MM, we employed an expression cDNA cloning system and isolated an unusual transforming mutant of H-Ras from the OPM-2 myeloma cell line. The H-Ras mutant identified contained a substitution in codon 117 that resulted in the replacement of lysine by glutamic acid. Mutations at H-Ras codon 117 have been previously described in chemically induced liver tumors in mice (Anna et al., 1994; Stanley et al., 1994) . The observed substitution disrupts a consensus sequence of Asn-Lys-X-Asp (Ras residues 116-119) commonly found in GTP-binding proteins (Der et al., 1986) . This region contains the segment of the guanine nucleotide binding pocket including amino acid 117 that interacts with the guanine ring (Figure 7) . Single amino-acid substitutions in these positions (116-119) generated by site-directed mutagenesis result in a reduction in binding affinity for GTP (Clanton et al., 1986; Walter et al., 1986) . It has been suggested that Ras (D119N) behaves as an activated mutant because of the strongly reduced nucleotide affinity enabling the mutant to bind GTP in a GEF-independent manner (Cool et al., 1999) . Since the physiological concentrations of GTP and GDP are thought to be in the ratio of 25 : 1 (Walter et al., 1986) , this increased exchange rate is proposed to favor the formation of the active GTP-bound form of Ras protein. It is interesting that the positions of common activating mutations (12, 13, and 61) are all proximal to the GTP phosphate groups (Tong et al., 1989; Milburn et al., 1990) . It is thus possible that the 117 mutation Figure 4 Mutant Ras activation in 32D-and B9-derivative cell lines. Cells were starved and then stimulated with either serum or murine IL-3 for 32D cells (a) or murine IL-6 for B9 cells (b) for 20 min. Lysates were immunoprecipitated with either GST-RBD for Ras activation assay or antiphospho-p44/42 MAP Kinase (Thr202/Tyr204) for MAP kinase assay. Cell lysates were analysed simultaneously for heat-shock protein 70 and p44/42 MAP kinase as controls for sample loading Unusual Ras mutation causing transformation C Crowder et al Figure 5 Mutant Ras expression promotes ANBL-6 growth at optimal and suboptimal concentrations of IL-6. Cells were seeded in triplicate at 2 Â l0 4 /ml in six-well plates in the presence of IL-6 at: 10 ng/ml, (a) and (e); 1 ng/ml, (b) and (f); and 0.1 ng/ml, (c) and (g); or no IL-6, (d) and (h). Cells were fed twice per week and viability determined at days 7 and 14 Unusual Ras mutation causing transformation C Crowder et al represents a separate class of mutants and, as such, we investigated associated biological properties.
Initial studies revealed that H-Ras was constitutively activated in OPM-2 cells, and that activation could be increased following IL-6 stimulation ( Figure 2 ). Interestingly, H-Ras was also constitutively activated in OPM-1, an independently derived line from the same patient. These two lines further shared a unique SSCP polymorphism in the region of mutation suggesting that the mutation had occurred in vivo. When expressed in 3T3 cells, the K117E mutant generated tumors in vivo at the same frequency as a position 12 mutant (Table 1) . As cytokines appear to play an important role in myeloma development, we examined the effects of the K117E mutant on IL-3-and IL-6-dependent cell growth. IL-6 has been suggested to be a major growth factor in MM (Klein et al., 1995) and has been shown to be essential for the development of plasma cell tumors in vivo (Hilbert et al., 1995; Lattanzio et al., 1997) . IL-3 has also been demonstrated to enhance proliferation of myeloma explants (Bergui et al., 1989; Klein and Bataille, 1992) . Transfection of the K117E mutant into IL-3 dependent 32D cells leads to outgrowth of cells that were completely IL-3 independent (Figure 3) . It is noteworthy that a position 12 activating mutation was not able to relieve IL-3 dependence in agreement with a previous report (Cristofanelli et al., 2000) . Thus, the 117 mutant clearly displays functional differences in comparison to those in the 12/13 region. Similar experiments using the IL-6-dependent B9 hybridoma line, again, lead to development of IL-6 independent cultures. Previous studies have shown that an N-Ras position 12 or 61 mutant was able to facilitate growth of myeloma cells at suboptimal IL-6 concentrations, whereas a position 12 K-Ras mutant could not (Billadeau et al., 1997) . The K117E mutant readily supported growth of IL-6-dependent ANBL-6 at concentrations where control cells failed to proliferate ( Figure 5 ) and, in this respect, functionally resembled the N-Ras (G12V) mutant. However, N-Ras (G12V) induced proliferation in the absence of IL-6, whereas H-Ras (K117E) did not. The mechanism of the H-Ras (K117E)-induced factorindependent growth is currently under investigation.
The IL-6 signaling pathway has been the subject of extensive studies in myeloma as a reflection of the likely importance of this cytokine in disease development. Binding of IL-6 to its receptor leads to phosphorylation of Janus kinases and Stat3 (Guschin et al., 1995; Heinrich et al., 1998) . Stat3 phosphorylation results in dimerization, translocation to the nucleus, DNA binding, and gene regulation (Ihle, 2001) . The critical role of Stat3 in IL-6 signaling is further demonstrated by observations indicating that constitutive Stat3 phosphorylation is associated with IL-6-independent plasma cell growth (Hilbert et al., 1996; Rawat et al., 2000) . It is of interest that the loss of IL-6 dependence imparted by the K117E mutant is not reflected in Stat3 phosphorylation (Figure 6 ) indicating that IL-6 Figure 6 Mutant Ras activation in ANBL-6 cell line. H-Ras (K117E) or vector-transfected ANBL-6 cells were starved for 18 h and then treated with IL-6 at 1 and 50 ng/ml for 20 min. Heat-shock protein 70 was used as a control for sample loading. (a) Ras activation was performed as described in Materials and methods. (b) The same lysates were used to immunoprecipitate Stat3, followed by blotting with antibodies to phospho-tyr705-Stat3 or Stat3
Unusual Ras mutation causing transformation C Crowder et al dependence can be overcome by mechanisms unrelated to Stat signaling. The present studies have identified a rare Ras mutant in which a single substitution leads to the ability to transform and relieve growth factor dependence for two cytokines which use independent signaling pathways. Mutations in this region of the molecule appear to be rare as this is, to our knowledge, the first such description observed in a human tumor line. However, it is not clear how carefully this region has been analysed in comparison to the 12/13 and 61 sites. Although the present studies provide no evidence that the 117 mutation is a frequent or important event in myeloma development in general, the findings may indicate that a further evaluation of this segment in the Ras family of proteins is warranted as mutations in this region clearly are associated with important physiological phenotypes that are likely to be significant in neoplastic development.
Materials and methods
Cell lines and cell culture
Human myeloma cell lines were kindly provided by Dr W Michael Kuehl (NCI, Bethesda, MD, USA). ANBL-6/pLXSN and ANBL-6/N-Ras (G12V) were the generous gift of Dr Brain Van Ness (University of Minnesota, Minneapolis, MN, USA). All myeloma cell lines except ANBL-6 were maintained in RPMI1640 (Biofluids, Rockville, MD, USA) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, and 50 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA). Human IL-6-dependent myeloma cell line ANBL-6 was grown in a medium containing 10 ng/ml IL-6. Murine IL-6-dependent hybridoma B9 cells were cultured in RPMI1640, supplemented with 10% heat-inactivated FBS and 5000 B9 U/ ml IL-6. Murine IL-3-dependent 32D C13 (G) cells were maintained in RPMI1640, supplemented with 15% heatinactivated FBS and 5% conditioned medium from the murine myelomonocytic cell line WEHI-3B as a source of IL-3.
cDNA library construction
An expression cDNA library was constructed from the OPM-2 human MM cell line. Smart PCR cDNA synthesis kit (Clontech, Palo Alto, CA, USA) was used to generate cDNAs from poly A + RNA by primer extension. cDNAs were ligated into lpCEV29 vector using directional cloning as previously described (Miki et al., 1989) The library was amplified and introduced into low-passage NIH3T3 cells by standard calcium phosphate treatment. Foci were isolated and plasmid rescue performed (Miki and Aaronson, 1995) . Rescued plasmids were subjected to sequence analysis.
RT-PCR
In vitro analysis for mutated H-Ras gene was performed by RT-PCR using the ProSTAR Ultra High Fidelity RT-PCR System (Stratagene, La Jolla, CA, USA). Briefly, first-strand cDNA was synthesized by reverse transcription of 1 mg total RNA isolated from the OPM-2 cell line. cDNA was amplified using two primer sets with a common sense primer and antisense primers specific for H-Ras position 117 mutant or wild-type sequence. Primers were as follows: Sense (F) primer, 5 0 -CGGAAGCAGGTGGTCATTGATG; antisense mutant (mt) primer, 5 0 -GCGTGCAGCCAGGTCACACTT; antisense wild-type (wt) primer, 5 0 -GCGTGCAGCCAGGTCACACTC. PCR samples were subjected to 40 cycles of amplification under the conditions of incubation at 951C for 30 s, 651C for 30 s, and 721C for 1 min. Reaction mixtures were separated on 1.5% agarose gels.
PCR-SSCP analysis
Genomic DNA was isolated using Blood & Cell Culture DNA Mini Kit (QIAGEN, Valencia, CA, USA). A total of 100 ng of genomic DNA was amplified by using TITANIUM Taq PCR kit (Clontech) with the following cycling parameters: 951C for 
H-Ras is activated only in IL-6 stimulated (50 ng/ml) ANBL-6 DW: direct western blot analysis; AA: Ras activation assay; ND: not determined Figure 7 Three-dimensional structure of the active site of the Ras-GTP complex. The guanine triphosphate, in gray, is located in a deep pocket. Mutations of amino acids 12, 13, and 61 forming a portion of the pocket are typically transforming. The region including residue 117 represents a contact site with the pyrimidine ring of guanine, whereas residues 12, 13, and 61 are proximal to the phosphate groups. The figure was generated using the Cn3D program downloaded from the NCBI website and based on crystallographic coordinates in the database (Pai et al., 1989) . N and C indicate amino-and carboxy-terminal ends, respectively 0 -CGATGTAGGGGATGCCGTAGC-3 0 . Cloning and transformation of the PCR mixture were performed using TOPO TA Cloning Kit for Sequencing (Invitrogen). Clones were directly analysed by PCR using the same conditions as above. Inserts were confirmed by visualization on 4% NuSieve agarose gels. For SSCP analysis, 1 m1 of PCR mixture was added to 9 m1 of stop solution (95% formamide, 10 mm NaOH, 0.25% bromophenol blue, and 0.25% xylene cyanol). Samples were heated to 951C for 3 min, snap-cooled on ice, then run on a non-denaturing MDE gel (BioWhittaker Molecular Applications, Rock1and, ME, USA) according to the manufacturer's instructions. Bands were detected using Silver Stain Plus (BioRad Laboratories, Hercules, CA, USA).
Transfections and Infections
Exponentially growing 32D cells (9 Â l0 6 ) were transfected by electroporation (0.3 kV, 960 mF) with pCEV29 carrying either H-Ras (G12V), or H-Ras (K117E), or pBW1631 containing wild-type H-Ras cDNA. After 18 h, cells were subjected to G418 selection (750 mg/ml) for 14 days. For infection of B9 and ANBL-6 cells, a VSV-G pseudotyped retrovirus system was used. H-Ras (K117E) cDNA was released from rescued plasmid pCEV29 by SalI enzyme digestion. The cDNA was ligated into pFB-neo retroviral vector (Stratagene) at the SalI site. Orientation of the cDNA was confirmed by sequence analysis. In all, 4 mg of the viral construct and 1 mg of pVPack-VSV-G plasmid were cotransfected into 10 6 BOSC-23 packaging cells (Pear et al., 1993) using Lipofectamine Plus Reagent (Invitrogen). After 48 h, viral supernatant was collected and passed through a 0.45-mm filter (Millipore Corporation, Bedford, MA, USA). The titer of the retroviral supernatant as determined on NIH 3T3 cells was in the range of 10 5 -10 6 CFU/ml. To infect B9 and ANBL-6, 2 Â 10 5 cells in 2.0 ml growth medium were cultured with 1 ml virus supernatant containing 4 mg/ml polybrene for 48 h. The cells were then selected in growth medium containing G418 (1 mg/ml for B9, 400 mg/ml for ANBL-6) for approximately 1 month.
Establishment of factor-independent cell lines
The isolation of factor-independent cell lines was accomplished by a stepwise withdrawal of growth factors. Cells were first shifted into media containing 50% less growth factor for 1-2 weeks, then to 90% less growth factor for another 1-2 weeks. Finally, cells were cultured in media without added growth factors.
Western blot analysis
Cells were washed twice with 1 Â PBS, then seeded in RPMI 1640 (18 h for OPM-2 and ANBL-6, 5 h for 32D and B9 parental cells and Ras mutants). The cells were then restimulated with either serum or growth factors as indicated in figure legends. Cells were lysed in buffer containing 20 mm Tris-Cl pH 7.5, 50 mm NaCl, 1% (v/v) NP40, 5 mm EDTA, 10 mm sodium pyrophosphate, 20 mg/ml aprotinin, 20 mg/ml leupeptin, 1 mm sodium orthovanadate, 1 mm AEBSF, and 50 mm sodium fluoride. The cell lysates were centrifuged at 15 000 g for 20 min at 41C. Protein concentration of the cell extracts was determined using BCA Protein Assay (Pierce, Rockford, II, USA). For direct Western blot analysis, 20 mg of total lysates was fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF membrane (Millipore). Blots were probed with antibodies specific for HRas, N-Ras, or K-Ras (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Goat anti-rabbit IgG horseradish peroxidase (Santa Cruz Biotechnology Inc.) was used as secondary antibody. Blots were developed by enhanced chemiluminescence (Pierce).
Ras activation assay
Ras activity was determined using a Ras Activation Assay kit (Upstate, Lake Placid, NY, USA). Briefly, cells were incubated in lysis buffer containing Mg 2+ . A total of 1 mg protein extract from each sample was then incubated with GST-RBDconjugated sepharose for 1 h at 41C with rocking. Bound proteins were eluted with SDS-PAGE sample buffer, resolved on 14% acrylamide gels, and subjected to Western blotting. Equal protein loading was confirmed by Hsp70 detection.
P44/42 MAP kinase assay
MAP kinase activity was measured using a nonradioactive kit (Cell Signaling Technology, Beverly, MA, USA) following the manufacturer's instructions. Briefly, 1 mg of total protein extract for each sample was immunoprecipitated with immobilized phospho-p44/42 MAP kinase (Thr202/Tyr204) monoclonal antibodies at 41C for 4 h. Pellets were washed and kinase assay was performed by using Elk-1 fusion protein as substrate. The samples were then analysed by Western blotting using phospho-Elk-1 antibody. P44/42 protein detection was used to ensure equal protein loading.
Cell proliferation assay
Cultures were initiated at 2 Â 10 4 cells/ml in a medium that either contained or lacked growth factor. Cell proliferation was monitored using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) following the manufacturer's instructions. Briefly, 2 Â 10 4 cells/ml were seeded in triplicate wells in six-well plates. At various time points, 100 ml of the culture was added to 96-well plates containing 20 ml CellTiter 96 Aqueous One Solution reagent and incubated at 371C for 4 h. The absorbance at 490 nm was recorded using a 96-well plate reader. All experiments were repeated at least twice.
